Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Gilead Sciences (GILD)

Gilead Q4 revenue rises 5% to $7.9 billion; 2026 diluted EPS guided at $6.75 to $7.15

Positive Impact 3 of 5 earnings Written later

Gilead reported fourth quarter and full year 2025 results on February 10, 2026. Fourth quarter revenue rose 5% to $7.9 billion and GAAP diluted EPS rose to $1.74 from $1.42, while non-GAAP diluted EPS fell to $1.86 from $1.90. The company also issued full year 2026 guidance, with diluted EPS of $6.75 to $7.15 and non-GAAP diluted EPS of $8.45 to $8.85.

Key points

  • Q4 2025 total revenues rose 5% to $7.9 billion; Q4 diluted EPS was $1.74 versus $1.42 a year earlier
  • Q4 2025 non-GAAP diluted EPS was $1.86 versus $1.90, reflecting higher acquired IPR&D expenses of $539 million
  • Full year 2025 revenues rose 2% to $29.4 billion; diluted EPS was $6.78 versus $0.38 in 2024
  • 2026 guidance: product sales of $29.6 billion to $30.0 billion; the board declared a $0.82 quarterly dividend payable March 30, 2026

The filing

CompanyGilead Sciences (GILD)
Form8-K, current report
Filed with the SECFeb 10, 2026, 4:02 PM ET
Accession number0000882095-26-000003

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.